Literature DB >> 15264438

Technology evaluation: rh lactoferrin, Agennix.

Jeanette H Andersen1.   

Abstract

Agennix is developing recombinant human (rh) lactoferrin, a glycoprotein with antibiotic, anti-inflammatory and immunomodulatory activity, for the potential treatment of cancers, asthma and chronic wounds. rh Lactoferrin is currently undergoing phase II clinical trials.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15264438

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  3 in total

Review 1.  Antimicrobial proteins and polypeptides in pulmonary innate defence.

Authors:  Mark P Rogan; Patrick Geraghty; Catherine M Greene; Shane J O'Neill; Clifford C Taggart; Noel G McElvaney
Journal:  Respir Res       Date:  2006-02-17

2.  Neolactoferrin as a stimulator of innate and adaptive immunity.

Authors:  A D Chernousov; M F Nikonova; N I Sharova; A N Mitin; M M Litvina; P E Sadchikov; I L Goldman; A A Yarilin; E R Sadchikova
Journal:  Acta Naturae       Date:  2013-10       Impact factor: 1.845

Review 3.  Growth factors for treating diabetic foot ulcers.

Authors:  Arturo J Martí-Carvajal; Christian Gluud; Susana Nicola; Daniel Simancas-Racines; Ludovic Reveiz; Patricio Oliva; Jorge Cedeño-Taborda
Journal:  Cochrane Database Syst Rev       Date:  2015-10-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.